Targeted delivery and apoptosis induction of CDK-4/6 inhibitor loaded folic acid decorated lipid-polymer hybrid nanoparticles in breast cancer cells

Rajana, Naveen; Sandeep Chary, Padakanti; Bhavana, Valamla; Deshmukh, Rajeshwari; Dukka, Komalatha; Sharma, Anamika; Kumar Mehra, Neelesh

doi:10.1016/j.ijpharm.2024.123787

Cited by 8 publications

(1 citation statement)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the formulation does not have diagnostic properties and was not evaluated for in vivo efficacy. 36 In another study, Dhamija et al developed PCBloaded redox-sensitive NPs as a smart drug delivery for breast cancer treatments. However, this study explored the therapeutic efficacy in vitro and in vivo models, but the designed delivery system was not for active targeting of overexpressed folate receptors in breast cancer.…”

Section: Introductionmentioning

confidence: 99%

PLGA Nanoplatform for the Hypoxic Tumor Delivery: Folate Targeting, Therapy, and Ultrasound/Photoacoustic Imaging

Mehata,

Bonlawar,

Tamang

et al. 2024

ACS Appl. Bio Mater.

View full text Add to dashboard Cite

Effective targeting of breast tumors is critical for improving therapeutic outcomes in breast cancer treatment. Additionally, hypoxic breast cancers are difficult to treat due to resistance toward chemotherapeutics, poor vascularity, and enhanced angiogenesis, which complicate effective drug delivery and therapeutic response. Addressing this formidable challenge requires designing a drug delivery system capable of targeted delivery of the anticancer agent, inhibition of efflux pump, and suppression of the tumor angiogenesis. Here, we have introduced Palbociclib (PCB)-loaded PLGA nanoparticles (NPs) consisting of chitosan-folate (CS-FOL) for folate receptor-targeted breast cancer therapy. The developed NPs were below 219 nm with a smooth, spherical surface shape. The entrapment efficiencies of NPs were achieved up to 85.78 ± 1.8%. Targeted NPs demonstrated faster drug release at pH 5.5, which potentiated the therapeutic efficacy of NPs due to the acidic microenvironment of breast cancer.In vitro cellular uptake study in MCF-7 cells confirmed the receptor-mediated endocytosis of targeted NPs. In vivo ultrasound and photoacoustic imaging studies on rats with hypoxic breast cancer showed that targeted NPs significantly reduced tumor growth and hypoxic tumor volume, and suppressed angiogenesis.

show abstract

Section: Introductionmentioning

confidence: 99%